Biosimilar Monoclonal Antibodies Market Top Companies Study - Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon.

Biosimilar Monoclonal Antibodies Market worth $ 36.85 Billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the most recent research, the worldwide biosimilar monoclonal antibodies market is valued at US$ 4.98 billion in 2021 and is predicted to reach US$ 36.85 billion by 2030, with a 25% CAGR during the forecast period 2022-2030.

Get Free Access to Demo Report, Excel Pivot and ToC: www.insightaceanalytic.com/request-sample/1218

Biosimilars are biotherapeutic compounds. They meet the same quality, effectiveness, and safety standards as a new reference pharmaceutical product. mAb biosimilars are complicated biological macromolecules with numerous post-translational changes. These biosimilars are widely used to treat chronic, inflammatory, and autoimmune illnesses. Biosimilars are regulated by several governing agencies in different countries, including the FDA in the United States and the European Medicines Agency (EMEA) in Europe.

Several factors contribute to the growth of the global biosimilar monoclonal antibodies market, including rising demand for cost-effective biosimilars, increased production of advanced monoclonal antibodies, an aging population, and a high prevalence of chronic diseases such as cancer, kidney failure, rheumatoid arthritis, psoriasis, diabetes, and others. Furthermore, increasing patent expiries for several mAbs are likely to improve market growth potential in the next years. Increased patent expirations of top-selling antibodies have prompted pharmaceutical companies to create biosimilars for mAbs, which is expected to boost the market throughout the forecast period.

However, the market's growth is expected to be hampered by the complexities of manufacturing biological drugs, a scarcity of clinical trial expertise, stringent government policies for product approvals, and manufacturers' lack of knowledge and understanding of biosimilars regulation and approval.

The Asia Pacific region is expected to develop significantly throughout the projection period (2020-2030) due to the growing burden of chronic diseases, the increasing need for cost-effective therapies, and increased government spending for healthcare facility improvements.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Major market players operating in the biosimilar monoclonal antibodies market include Pfizer (US), Novartis (Switzerland), Allergan (Ireland), Coherus BioSciences (US), Biocon (Bengaluru), Amgen (US), Boehringer Ingelheim (Germany), Celltrion (South Korea), BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia) among others.

Key developments in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support biosimilar development for third-party customers. This partnership created an integrated solution between two leading service providers in biosimilar development and GMP manufacture.
• In February 2020, Mylan (US) launched its trastuzumab biosimilar, Ogivri. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-receptor-positive breast cancer, previously marketed by Genentech as Herceptin.
• In June 2019, Amgen (US) and Allergan (Ireland) announced the FDA approval for KANJINTI™ (trastuzumab-anns). It is approved for all indications of the reference product, Herceptin® (trastuzumab), providing an additional treatment option for patients across three types of cancer.

Unlock Your GTM Strategy: www.insightaceanalytic.com/customisation/1218

Market Segments
Biosimilar Monoclonal Antibodies Market, by Product, 2020-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Biosimilar Monoclonal Antibodies Market, by Indication, 2020-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Biosimilar Monoclonal Antibodies Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ www.insightaceanalytic.com/buy-report/1218

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.